Contineum Therapeutics's three largest insider shareholders as of September 29, 2026 are Venture Capital Vi, L.P. Versant (TenPercentOwner, 148.31K shares), Daniel S. Lorrain (Chief Scientific Officer, 135.20K shares), Carmine N. Stengone (Ceo And President, 17.22K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Venture Capital Vi, L.P. Versant | TenPercentOwner | 0 | 148,312 | 148,312 | 46.0% | 11 Apr, 2024 |
| 2 | Daniel S. Lorrain | Chief Scientific Officer | 135,202 | 0 | 135,202 | 41.9% | 10 Jul, 2026 |
| 3 | Carmine N. Stengone | Ceo And President | 17,217 | 0 | 17,217 | 5.3% | 08 Sep, 2026 |
| 4 | Stephen L. Huhn | Cmo Sr Vp, Clinical Dev. | 12,800 | 0 | 12,800 | 4.0% | 14 Aug, 2024 |
| 5 | Tim Watkins | Cmo Head Of Development | 8,961 | 0 | 8,961 | 2.8% | 01 Jul, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 08 Sep, 2026 | Carmine N. Stengone | Ceo And President | Acquired M | 2,500 | $1.01 | $2.53K | 19,717 | Direct |
| 08 Sep, 2026 | Carmine N. Stengone | Ceo And President | Disposed S | 2,500 | $16.46 | $41.14K | 17,217 | Direct |
| 08 Sep, 2026 | Carmine N. Stengone | Ceo And President | Disposed M | 2,500 | $0.00 | $0 | 274,430 | Direct |
| 03 Aug, 2026 | Carmine N. Stengone | Ceo And President | Acquired M | 2,500 | $1.01 | $2.53K | 19,717 | Direct |
| 03 Aug, 2026 | Carmine N. Stengone | Ceo And President | Disposed S | 2,500 | $16.01 | $40.03K | 17,217 | Direct |
| 03 Aug, 2026 | Carmine N. Stengone | Ceo And President | Disposed M | 2,500 | $0.00 | $0 | 276,930 | Direct |
| 08 Jul, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Acquired M | 1,015 | $1.01 | $1.03K | 136,217 | Direct |
| 08 Jul, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Disposed S | 1,015 | $16.00 | $16.24K | 135,202 | Direct |
| 09 Jul, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Acquired M | 25 | $1.01 | $25 | 135,227 | Direct |
| 09 Jul, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Disposed S | 25 | $16.00 | $400 | 135,202 | Direct |
| 08 Jul, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Disposed M | 1,015 | $0.00 | $0 | 33,282 | Direct |
| 09 Jul, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Disposed M | 25 | $0.00 | $0 | 33,257 | Direct |
| 08 Jul, 2026 | Carmine N. Stengone | Ceo And President | Acquired M | 2,500 | $1.01 | $2.53K | 19,717 | Direct |
| 08 Jul, 2026 | Carmine N. Stengone | Ceo And President | Disposed S | 2,500 | $16.00 | $40.00K | 17,217 | Direct |
| 08 Jul, 2026 | Carmine N. Stengone | Ceo And President | Disposed M | 2,500 | $0.00 | $0 | 279,430 | Direct |
| 30 Jun, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Acquired M | 28,826 | $1.01 | $29.11K | 168,198 | Direct |
| 30 Jun, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Disposed S | 28,826 | $16.04 | $462.29K | 139,372 | Direct |
| 01 Jul, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Acquired M | 4,183 | $1.01 | $4.22K | 143,555 | Direct |
| 01 Jul, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Disposed S | 5,852 | $15.67 | $91.68K | 137,703 | Direct |
| 01 Jul, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Disposed S | 2,501 | $16.24 | $40.61K | 135,202 | Direct |